时间:2024-12-24
Jian-Bin Zhang, Jie Chen, Jin Zhou, Xu-Ming Wang, Shu Chen, Jian-Guo Chu, Peng Liu, Zhi-Dong Ye
Jian-Bin Zhang, Jie Chen, Jin Zhou, Xu-Ming Wang, Peng Liu, Zhi-Dong Ye, Department of Cardiovascular Surgery, China-Japan Friendship Hospital, Beijing 100029, China
Shu Chen, Department of Interventional Radiology, Affiliated People’s Hospital of Inner Mongolia Medical University, Hohhot 010020, Inner Mongolia Autonomous Region, China
Jian-Guo Chu, Department of Radiology, Air Force Medical Center of PLA, Beijing 100142,China
Abstract BACKGROUND Portal vein thrombosis (PVT) was previously a contraindication for trans-jugular intrahepatic portosystemic shunt (TIPS).AIM To perform a systematic review and meta-analysis of the current available studies investigating outcomes of TIPS for cirrhotic patient with PVT.METHODS Multiple databases were systematically searched to identify studies investigating the outcomes of TIPS for cirrhotic patients with PVT. The quality of studies was assessed by Cochrane Collaboration method and Methodological Index for Non-Randomized Studies. The demographic data, outcomes, combined treatment, and anticoagulation strategy were extracted.RESULTS Twelve studies were identified with 460 patients enrolled in the analysis. The technical success rate was 98.9% in patients without portal vein cavernous transformation and 92.3% in patients with portal vein cavernous transformation.One-year portal vein recanalization rate was 77.7%, and TIPS patency rate was 84.2%. The cumulative encephalopathy rate was 16.4%. One-year overall survival was 87.4%.CONCLUSION TIPS is indicated for portal hypertension related complications and the restoration of pre-transplantation portal vein patency in cirrhotic patients with PVT.Cavernous transfor-mation is an indicator for technical failure. Post-TIPS anticoagulation seems not mandatory. Simultaneous TIPS and percutaneous mechanical thrombectomy device could achieve accelerated portal vein recanalization and decreased thrombolysis-associated complications, but further investigation is still needed.
Key Words: Trans-jugular intrahepatic portosystemic shunt; Portal vein thrombosis; Liver cirrhosis; Systematic review; Meta-analysis
Portal vein thrombosis (PVT) refers to thrombosis within the portal vein, including main trunk, splenic, or mesenteric vein. The prevalence of PVT in cirrhotic patients can reach to 36%, depending on the severity of liver disease and diagnostic method[1,2].Trans-jugular intrahepatic portosystemic shunt (TIPS) is indicated for cirrhotic patients with refractory ascites and variceal bleeding not controlled with medical or endoscopic therapy[3,4].
In cirrhotic patients with PVT, increased portal hypertension, decreased liver perfusion, and worsened liver function may occur[5]. Initially, PVT was regarded as contraindication for TIPS because of the technical difficulties, especially in patients with portal vein cavernous transformation[6]. However, some investigator attempted to carry out TIPS in cirrhotic patients with PVT and achieved good results[7]. The theoretical basis is that TIPS can increase portal blood velocity, resulting in clot resorption and portal vein recanalization.
However, most of the relevant studies were anecdote-based, and the sample sizes were relatively small. At present, only limited data are available for TIPS in cirrhotic patients with PVT. Therefore, we wanted to review systematically the published data of TIPS for cirrhotic patients with PVT.
MEDLINE, CNKI, Google Scholar, EMBASE, and Cochrane database were systematically searched for all relevant published studies evaluating outcomes following TIPS in cirrhotic patients with PVT. Several combinations of search terms were used,including “trans-jugular intrahepatic portosystemic shunt,” “portal vein thrombosis,”“cavernous transformation,” “liver cirrhosis,” “variceal bleeding,” and “early TIPS.”Moreover, some journals in interventional radiology, gastroenterology, and vascular surgery were reviewed manually for relative articles.
Titles and abstracts of the papers were screened first. Only studies evaluating outcomes following TIPS in cirrhotic patients with PVT were included. Case reports and review articles were excluded.
Quality of randomized controlled trials were assessed using Cochrane Collaboration method. Quality of non-randomized studies were assessed using Methodological Index for Non-Randomized Studies scale[8].
Demographics and outcome data were extracted for each eligible paper.Demographic data included: (1) etiology of liver cirrhosis, (2) symptom and comorbidity, (3) thrombosis characteristics, (4) technical details, and (5) periprocedural anticoagulative strategies. Outcome data included: (1) technical success rate, (2) portal vein recanalization rate, (3) TIPS patency, (4) hepatic encephalopathy rate, and (5)survival.
Intraclass correlation coefficient was calculated for evaluating the level of agreement between investigators assessing the study quality. means ± SD of both Methodological Index for Non-Randomized Studies score and Cochrane Collaboration method score were calculated.
Funnel plot was used for assessing publication bias. Study heterogeneity was tested usingQstatistic, withP﹤ 0.1 indicating significance. SPSS 22 (SPSS Inc., Armonk, NY,United States) and Open Meta-Analyst software (http://www.cebm.brown.edu/openmeta/download.html) were used for data analysis.
Twelve papers published over the past 15 years, reporting a total of 460 patients, were included in the study[1,2,4,9-17] (Figure 1). The included study characteristics are shown in Table 1. Of these studies, nine were retrospective and three were randomized controlled trials[1,12,13]. All these studies evaluated TIPS for PVT in liver cirrhotic patients; one was for pre-transplantation patients.
Table 1 Characteristics of the included studie s
Figure 1 PRISMA flow chart for the selection process. TIPS: Trans-jugular intrahepatic portosystemic shunt.
EBL: Endoscopic banding ligation; MPV: Main portal vein; N/A: Not applicable; NSBB: Non-selective beta-blocker; PVT: Portal vein thrombosis; RCT:Randomized controlled trial; TIPS: Trans-jugular intrahepatic portosystemic shunt.
Except for one that did not report indication[13], the main indication for TIPS was to treat complications of portal hypertension. Treating gastrointestinal variceal bleeding or preventing re-bleeding was reported in 77.01% of patients, and treating refractory ascites or pleural effusion was reported in 15.82% of patients. In one study[17], TIPS was utilized for the restoration of portal vein patency.
Demographics and results of the included studies are shown in Table 2.
Table 2 Demographics and results of the included studies
The overall technical success rate for TIPS was 94.6% (435/460) for all the included studies. In patients with portal vein cavernous transformation, the lowest technical success rate was 53.33%, as reported by Hanet al[9]. The cumulative technical success rate was 98.9% in patients without portal vein cavernous transformation and 92.3% in patients with portal vein cavernous transformation[1,2,11,14,16]. Most of the TIPS was achieved through a traditional trans-jugular approach; trans-hepatic and trans-splenic approach was employed to facilitate portal recanalization or to target the punctured vessel.
One-year portal vein recanalization rate was 77.7%, and TIPS patency rate was 84.2%.TIPS combined with AngioJet thrombectomy device was reported by Zhanget al[16],and the portal vein recanalization rate was reported to be 81.8%. Lucaet al[11]reported that independent predictors for portal vein recanalization were thrombosis of a single vein, PVT severity of grade I,de novodiagnosis of PVT, and absence of gastroesophageal varices.
Nine studies[1,4,9-13,16,17] reported hepatic encephalopathy rate. The highest 1-yearhepatic encephalopathy rate was 27%, reported by Lucaet al[11]. The overall 1-year encephalopathy rate was 16.4%. The highest 2-year encephalopathy rate was 38.5%,reported by Luoet al[1].
Most of the studies reported 1-year survival rates, and they ranged from 75% to 98.4%.The overall 1-year survival was 87.4%. Two studies[9,17] reported a 5-year survival rates of 82% and 76.7%, respectively. Hanet al[9] reported that both technical success and survival were closely associated with the degree of main portal vein occlusion.
Most studies did not have unified standard for anticoagulation strategy. Only one study[13] evaluated whether post-TIPS anticoagulation was necessary. The result showed that anticoagulation therapy may not be necessary in certain patients with PVT because TIPS placement alone can achieve a high persistent recanalization rate.
The primary etiology of PVT is decompensated cirrhosis, especially those with splenectomy. Patients with prior splenectomy have a higher incidence of PVT, which can influence the technical success and patency rate of TIPS[18].We suggest that patients with portal hypertension should avoid splenectomy if they plan to receive TIPS treatment.
PVT in cirrhotic patients is most often asymptomatic and detected incidentally on routine ultrasound[19]. Spontaneous resolution occurs in approximately 40% of PVT[20]. Symptoms may vary from asymptomatic to life-threatening conditions related to portal hypertension and hepatic decompensation[21]. The treatment strategy for PVT includes anti-coagulation, thrombolysis, and thrombectomy. TIPS is an effective adjunctive therapy to recanalize the portal vein and reduce portal hypertension. For PVT patients with obvious portal hypertensive symptoms, such as recurrent gastrointestinal bleeding or refractory ascites, TIPS is the only way to improve hepatopetal flow and offers a low-resistance outflow channel.
TIPS placement is challenging in advanced occlusive PVT thrombosis and portal vein cavernous transformation. As the current study reported, the lowest technical success rate was reported to be 53.33% in portal vein cavernous transformation[9].Some investigators regarded portal cavernous transformation as a contraindication for TIPS because the original portal vein has been obliterated or has become a fibrotic cord[22]. It has come a long way from being a contraindication to an indication because of technical difficulties and frequent procedure related complications. Combined transjugular/trans-hepatic or trans-jugular/trans-splenic approach could improve technical success rate[23].
The successful employment of percutaneous mechanical thrombectomy device in PVT has been reported[24,25]. It is more suitable for acute or subacute PVT with accelerated portal vein recanalization and decreased thrombolysis-associated complications. Simultaneous creation of TIPS could reconstruct portal outflow and further improve therapeutic effect. But most of the associated studies were case reports or small case series. Larger patient cohorts should be evaluated for further analysis.
PVT was thought to have a negative impact on liver cirrhosis progression and patient survival because it further increased portal hypertension, which may lead to life-threating complications and worsening liver function[21]. A meta-analysis including 2436 cirrhotic patients suggested that PVT appears to increase mortality and ascites[26]. In the current study, TIPS could not improve the survival of cirrhotic patients with PVT but could alleviate the portal hypertension related complications and improve quality of life, without an increase in hepatic encephalopathy.
Another indication of TIPS for cirrhotic patients with PVT was to maintain pretransplantation portal vein patency. Portal vein recanalization-TIPS is a concept aimed at achieving portal vein recanalization in chronic PVT[27]. In these patients, the stent should be implanted in the main portal vein as short as possible to reserve sufficient non-stented PV for end-to-end anastomosis during liver transplantation.
Wanget al[13] suggested that increased portal blood velocity after TIPS may offset the hypercoagulable state and result in portal recanalization even without anticoagulation. In addition, the safety of anticoagulation drugs is also a problem, especially in cirrhotic patients. The study, however, did not included PVT in the entire portal venous system because TIPS procedure in those patients is quite difficult. Thus, the value of post-TIPS anticoagulation should be further investigated in patients with diffuse PVT.
Limitations may exist in our study. First, the pooled analysis was based on studylevel data (Figure 2). Second, only three of the included studies were random controlled trials, and the others were retrospective cohort studies. Therefore, heterogeneity may exist among the studies.
Figure 2 Forrest plots of pooled analysis. A: Technical success rate without portal vein cavernous transformation; B: Technical success rate with portal vein cavernous transformation; C: 1-yr portal vein recanalization rate; D: 1-yr TIPS patency rate; E: 1-yr encephalopathy rate; F: 1-yr survival rate. CI: Confidence interval; TIPS: Trans-jugular intrahepatic portosystemic shunt.
In conclusion, TIPS is indicated for portal hypertension related complications and the restoration of pre-transplantation portal vein patency in cirrhotic patients with PVT.Cavernous transformation is an indicator for technical failure. Post-TIPS anticoagulation seems not mandatory. Simultaneous TIPS and percutaneous mechanical thrombectomy device could achieve accelerated portal vein recanalization and decreased thrombolysis-associated complications, but further investigation is still needed.
In clinical practice, portal vein thrombosis (PVT) was previously a contraindication for trans-jugular intrahepatic portosystemic shunt (TIPS).
Evaluating TIPS utility in the management of cirrhotic patients with PVT.
To review systematically t he current evidence of TIPS in the management of cirrhotic patients with PVT.
Search and evaluate the r elevant published paper and then extract and analyze the key data.
TIPS can be safely carried out using a different approach in cirrhotic patient with PVT.However, in patients with cavernous transformation, it is relatively difficult.
TIPS is indicated for portal hypertension related complications and the restoration of pre-transplantation portal vein patency in cirrhotic patients with PVT. Cavernous transformation is an indicator for technical failure.
TIPS could be carried out in most of cirrhotic patients with PVT. We plan to carry out a similar study with a prospective design to evaluate TIPS utility for patients with PVT.
我们致力于保护作者版权,注重分享,被刊用文章因无法核实真实出处,未能及时与作者取得联系,或有版权异议的,请联系管理员,我们会立即处理! 部分文章是来自各大过期杂志,内容仅供学习参考,不准确地方联系删除处理!